Saturday, April 23, 2016 11:24:49 AM
1.) Insurance cost surely was a legitimate reason
2.) Lack of training on amount and overall usage requirements
So if I'm right then it comes down to how does this changes and its two fold:
1.) Better insurance coverage which is coming and has continued to improve.
2.) Out patient centers that have trained practioners who will work with the diabetic community and more overall Physicians being educated thru the new MNKD sales force.
These out patient centers see hundreds of people on a regular basis and can drastically improve script counts in just the first 90 days of existence. Once the word is out and the script counts get up into the thousands it will be very difficult to hold back the ground swell.
Unfortunately, this looks like a second half of the year turn around story and if we get a better handling on the funding this Tuesday we should see a decent pop over $2 and will stabilize before moving to the next level.
Recent MNKD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2024 02:30:04 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:06:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:05:13 PM
- MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/07/2024 09:02:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/06/2024 09:04:14 PM
- MannKind to Present at 2024 UBS Healthcare Conference • GlobeNewswire Inc. • 11/05/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 02:00:03 AM
- MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases • GlobeNewswire Inc. • 11/04/2024 11:05:00 AM
- MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 • GlobeNewswire Inc. • 10/31/2024 08:05:00 PM
- More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®) • GlobeNewswire Inc. • 09/30/2024 10:00:00 AM
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 09/18/2024 10:15:00 AM
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference • GlobeNewswire Inc. • 09/10/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:11:49 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:25:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 09:23:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:28 PM
- MannKind to Present at Upcoming Conferences • GlobeNewswire Inc. • 08/27/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:03:59 PM
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM